Advances in treatment for relapses and refractory multiple myeloma

Medical Oncology

Volumn 27, Issue SUPPL. 1, 2010, Pages

  Richards, Tiffany ^a   Weber, Donna ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Multiple myeloma; Refractory; Relapsed; Treatment advances

Indexed keywords

ACETYLSALICYLIC ACID; BENDAMUSTINE; BORTEZOMIB; CARFILZOMIB; CISPLATIN; CNTO 328; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; LENALIDOMIDE; MELPHALAN; PANOBINOSTAT; PERIFOSINE; POMALIDOMIDE; PREDNISONE; ROMIDEPSIN; SALINOSPORAMIDE A; TANESPIMYCIN; TEMSIROLIMUS; THALIDOMIDE; VINCRISTINE; VORINOSTAT;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG DOSE REDUCTION; DRUG POTENTIATION; DRUG RESPONSE; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HEART ATRIUM FIBRILLATION; HUMAN; INFECTION; LEUKOPENIA; MULTIPLE MYELOMA; NAUSEA; NEUROLOGIC DISEASE; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; THROMBOCYTOPENIA; THROMBOEMBOLISM; VIRUS REACTIVATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; HUMANS; MULTIPLE MYELOMA; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PYRAZINES; RECURRENCE; THALIDOMIDE;

EID: 77954084358     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12032-009-9407-5     Document Type: Review

References (112)

1. R Alexanian B Barlogie S Tucker 1990 VAD-based regimens as primary treatment for multiple myeloma Am J Hematol 33 2 86 89 10.1002/ajh.2830330203 1:STN:280:DyaK3c7ksVKquw%3D%3D 2301376 (Pubitemid 20040083)
2. R Alexanian DE Bergsagel PJ Migliore WK Vaughn CD Howe 1968 Melphalan therapy for plasma cell myeloma Blood 31 1 1 10 1:STN:280:DyaF1c7ltV2rtw%3D%3D 5638562
3. R Alexanian MA Dimopoulos K Delasalle B Barlogie 1992 Primary dexamethasone treatment of multiple myeloma Blood 80 4 887 890 1:STN:280:DyaK38zmtVyltA%3D%3D 1498331
4. R Alexanian MA Dimopoulos KB Delasalle J Hester R Champlin 1995 Myeloablative therapy for primary resistant multiple myeloma Stem Cells 13 Suppl 2 118 121 8520499
5. M Attal J-L Harousseau A-M Stoppa, et al. 1996 A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma N Engl J Med 335 2 91 97 10.1056/NEJM199607113350204 1:STN:280:DyaK283ms1emuw%3D%3D 8649495 (Pubitemid 26240110)
6. S Singhal J Mehta R Desikan, et al. 1999 Antitumor activity of thalidomide in refractory multiple myeloma N Engl J Med 341 21 1565 1571 10.1056/NEJM199911183412102 1:CAS:528:DyaK1MXotVSgs78%3D 10564685
7. Anderson K, Jagannath S, Jakubowiak A, Lonial S, Raje N, Alsina M, Ghobrial I, Knight R, Esseltine D, Richardson P. Lenalidomide, bortezomib, and dexamethasone in relapsed/refractory multiple myeloma (MM): encouraging outcomes and tolerability in a phase II study. J Clin Oncol. 2009;27(15 s).
8. S Kumar IW Flinn SJ Noga, et al. 2008 Safety and efficacy of novel combination therapy with bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in newly diagnosed multiple myeloma: initial results from the phase I/II multi-center evolution study ASH Ann Meet Abstr 112 11 93
9. JL Harousseau C Mathiot M Attal, et al. 2007 VELCADE/dexamethasone (Vel/D) versus VAD as induction treatment prior to autologous stem cell transplantion (ASCT) in newly diagnosed multiple myeloma (MM): updated results of the IFM 2005/01 trial ASH Ann Meet Abstr 110 11 450
10. S Jagannath BG Durie J Wolf, et al. 2005 Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma British J Haematol 129 6 776 783 10.1111/j.1365-2141.2005.05540.x 1:CAS:528:DC%2BD2MXms1ehsLw%3D (Pubitemid 40904528)
11. SV Rajkumar S Jacobus N Callander, et al. 2007 A randomized trial of lenalidomide plus high-dose dexamethasone (RD) versus lenalidomide plus low-dose dexamethasone (Rd) in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group ASH Ann Meet Abstr 110 11 74
12. CB Reeder DE Reece R Fonseca, et al. 2007 A phase II trial of myeloma induction therapy with cyclophosphamide, bortezomib, and dexamethasone (Cybor-D): improved response over historical lenalidomide-dexamethasone controls ASH Ann Meet Abstr 110 11 3601
13. JA Zonder J Crowley MA Hussein, et al. 2007 Superiority of lenalidomide (Len) plus high-dose dexamethasone (HD) compared to HD alone as treatment of newly-diagnosed multiple myeloma (NDMM): results of the randomized, double-blinded, placebo-controlled SWOG trial S0232 ASH Ann Meet Abstr 110 11 77
14. DM Weber C Chen R Niesvizky, et al. 2007 Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America [see comment] N Engl J Med 357 21 2133 2142 10.1056/NEJMoa070596 1:CAS:528:DC%2BD2sXhtlGis7bM 18032763 (Pubitemid 350146108)
15. M Dimopoulos A Spencer M Attal, et al. 2007 Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma [see comment] N Engl J Med 357 21 2123 2132 10.1056/NEJMoa070594 1:CAS:528:DC%2BD2sXhtlGis7nN 18032762 (Pubitemid 350146107)
16. Reece D, Song KW, Fu T, et al. Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13. Blood 2009. blood-2008-12-193458.
17. S Jagannath PG Richardson P Sonneveld, et al. 2006 Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials Leukemia 21 1 151 157 10.1038/sj.leu.2404442 17096017
18. DE Reece E Masih-Khan A Khan, et al. 2008 Phase I-II trial of oral cyclophosphamide, prednisone and lenalidomide (revlimid(R)) (CPR) for the treatment of patients with relapsed and refractory multiple myeloma ASH Ann Meet Abstr 112 11 1723
19. DE Reece GP Rodriguez C Chen, et al. 2008 Phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma J Clin Oncol 26 29 4777 4783 10.1200/JCO.2007.14.2372 1:CAS:528:DC%2BD1cXhtlSqsb7J 18645194
20. S Knop C Gerecke P Liebisch, et al. 2009 Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom) Blood 113 18 4137 4143 10.1182/blood-2008-10-184135 1:CAS:528:DC%2BD1MXlvVGis7k%3D 19182205
21. A Palumbo P Falco G Sanpaolo, et al. 2008 Combination of lenalidomide, melphalan, prednisone and thalidomide (RMPT) in relapsed/refractory multiple myeloma: results of a multicenter phase II clinical trial ASH Ann Meet Abstr 112 11 868
22. M Kropff P Liebisch H Wand, et al. 2007 Dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed multiple myeloma ASH Ann Meet Abst 110 11 3599
23. E Colado M-V Mateos M-J Moreno, et al. 2008 VAMP/ThaCyDex: Velcade(R) (Bortezomib), adriamycin, melphalan and prednisone alternating with thalidomide, cyclophosphamide and dexamethasone as a salvage regimen in relapsed multiple myeloma patients ASH Ann Meet Abstr 112 11 3694
24. FE Davies P Wu M Jenner M Srikanth R Saso GJ Morgan 2007 The combination of cyclophosphamide, velcade and dexamethasone (CVD) induces high response rates with comparable toxicity to velcade alone (V) and velcade plus dexamethasone (VD) Haematologica 92 8 1149 1150 10.3324/haematol.11228 1:CAS:528: DC%2BD2sXhtFKrs77J 17650451 (Pubitemid 350144228)
25. SK Kumar SV Rajkumar A Dispenzieri, et al. 2008 Improved survival in multiple myeloma and the impact of novel therapies Blood 111 5 2516 2520 10.1182/blood-2007-10-116129 1:CAS:528:DC%2BD1cXivFaktrk%3D 17975015
26. R Garcia-Sanz JR Gonzalez-Porras JM Hernandez, et al. 2004 The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed//refractory multiple myeloma Leukemia 18 4 856 863 10.1038/sj.leu.2403322 1:CAS:528:DC%2BD2cXisVyqs74%3D 14973508 (Pubitemid 38500205)
27. DE Reece HA Leitch H Atkins, et al. 2008 Treatment of relapsed and refractory myeloma Leukemia Lymphoma 49 8 1470 1485 10.1080/10428190802064941 18608859
28. A Anagnostopoulos D Weber K Rankin K Delasalle R Alexanian 2003 Thalidomide and dexamethasone for resistant multiple myeloma British J Haematol 121 5 768 77 10.1046/j.1365-2141.2003.04345.x 1:CAS:528:DC%2BD3sXlt1Kmtb0%3D (Pubitemid 36718193)
29. M Roussou A Anagnostopoulos E Kastritis, et al. 2007 Pulsed cyclophosphamide, thalidomide and dexamethasone regimen for previously treated patients with multiple myeloma: long term follow up and disease control after subsequent treatments Leukemia Lymphoma 48 4 754 758 10.1080/10428190601186168 1:CAS:528:DC%2BD2sXnsVSjurY%3D 17454634 (Pubitemid 46605548)
30. C Kyriakou K Thomson S D'Sa, et al. 2005 Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma British J Haematol 129 6 763 770 10.1111/j.1365-2141.2005. 05521.x 1:CAS:528:DC%2BD2MXms1ehsL4%3D (Pubitemid 40904526)
31. A Palumbo I Avonto B Bruno, et al. 2006 Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma Eur J Haematol 76 4 273 277 10.1111/j.1600-0609.2005.00610.x 1:CAS:528: DC%2BD28XkvVOkurw%3D 16519697 (Pubitemid 43362934)
32. Weber DM GM, Delasalle K, et al. Thalidomide alone or with dexamethasone for multiple myeloma. Blood 1999;94(604a).
33. T Hideshima D Chauhan Y Shima, et al. 2000 Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy Blood 96 9 2943 2950 1:CAS:528:DC%2BD3cXnslGnsbw%3D 11049970
34. Zangari MBB, Jacobson J, et al. VTD regimen comprising velcade (V) + thalidomide (T) and added DEX (D) for non-responders to V + T effects a 57% PR rate among 56 patients with myeloma (M) relapsing after autologous transplant. Blood 2003;102(11).
35. C-K Lee B Barlogie N Munshi, et al. 2003 DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma J Clin Oncol 21 14 2732 2739 10.1200/JCO.2003.01.055 1:CAS:528:DC%2BD2cXptlCktbw%3D 12860952 (Pubitemid 46606319)
36. W Pönisch M Rozanski H Goldschmidt, et al. 2008 Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a phase I clinical trial British J Haematol 143 2 191 200 10.1111/j.1365-2141.2008.07076.x
37. T Morris P Kettle M Drake, et al. 2008 Clarithromycin with low dose dexamethasone and thalidomide is effective therapy in relapsed/refractory myeloma British J Haematol 143 3 349 354 10.1111/j.1365-2141.2008.07360.x 1:CAS:528:DC%2BD1cXhsVeqsLvN
38. MA Hussein R Baz G Srkalovic, et al. 2006 Phase 2 study of pegylated liposomal doxorubicin, vincristine, decreased-frequency dexamethasone, and thalidomide in newly diagnosed and relapsed-refractory multiple myeloma Mayo Clin Proc 81 7 889 895 10.4065/81.7.889 1:CAS:528:DC%2BD28Xntlanu7s%3D 16835968
39. GW Muller R Chen S-Y Huang, et al. 1999 Amino-substituted thalidomide analogs: potent inhibitors of TNF-[alpha] production Bioorg Med Chem Lett 9 11 1625 1630 10.1016/S0960-894X(99)00250-4 1:CAS:528:DyaK1MXjvVKisbs%3D 10386948 (Pubitemid 29274209)
40. PG Richardson RL Schlossman E Weller, et al. 2002 Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma Blood 100 9 3063 3067 10.1182/blood-2002-03-0996 1:CAS:528:DC%2BD38XosVSis78%3D 12384400 (Pubitemid 35217050)
41. Richardson P, Jagannath S, Hussein M, et al. Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma. Blood 2009. blood-2008-12-196238.
42. S Schey GJ Morgan K Ramasamy, et al. 2008 CRD: a phase 1 dose escalation study to determine the maximum tolerated dose of cyclophosphamide in combination with lenalidomide and dexamethasone in relapsed/refractory myeloma ASH Ann Meet Abstr 112 11 3707
43. Zangari M, Tricot G, Zeldis J, Eddlemon P, Saghafifar F, Barlogie B. Results of phase I study of CC-5013 for the treatment of multiple myeloma patients who relapse after high dose chemotherapy (HDCT). Blood 2001;775a.
44. Dimopoulos MA, Chen C, Spencer A, et al. Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia. 2009;23(11):2147-52.
45. A Palumbo SV Rajkumar MA Dimopoulos, et al. 2008 Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma Leukemia 22 2 414 423 10.1038/sj.leu.2405062 1:CAS:528:DC%2BD1cXhvVyltLc%3D 18094721 (Pubitemid 351255436)
46. M Wang MA Dimopoulos C Chen, et al. 2008 Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure Blood 112 12 4445 4451 10.1182/blood-2008-02-141614 1:CAS:528:DC%2BD1cXhsVCltb3M 18799726
47. D Weber M Wang C Chen, et al. 2006 Lenalidomide plus high-dose dexamethasone provides improved overall survival compared to high-dose dexamethasone alone for relapsed or refractory multiple myeloma (MM): results of 2 phase III studies (MM-009, MM-010) and subgroup analysis of patients with impaired renal function ASH Ann Meet Abstr 108 11 3547
48. N Chen H Lau L Kong, et al. 2007 Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis J Clin Pharmacol 47 12 1466 1475 10.1177/0091270007309563 1:CAS:528:DC%2BD2sXhsVyjtr7F 17954615 (Pubitemid 350115306)
49. Avet-Loiseau H, Soulier J, Fermand J, Facon T, Attal M, Harousseau J, Belhadj K, Hulin C, Garderet L, Dorvaux V, Moreau P. Impact of chromosomal abnormalities del (13), t(4:14), and del (17p) and prior treatment on outcomes in patients with relapsed or refractory multiple myeloma treated with lenalidomide. Blood 2008;112(11).
50. H Avet-Loiseau 2007 Role of genetics in prognostication in myeloma Best Prac Res Clin Haematol 20 4 625 635 10.1016/j.beha.2007.08.005 1:CAS:528:DC%2BD2sXhsVSksb%2FL (Pubitemid 350225352)
51. Avet-Loiseau H. Genetic implications in myeloma: prognostic implications. Clin Lymphoma myeloma 2009;9(S2).
52. A Palumbo P Falco P Corradini, et al. 2007 Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA Italian multiple myeloma network J Clin Oncol 25 28 4459 4465 10.1200/JCO.2007.12.3463 1:CAS:528:DC%2BD2sXht1ertrjK 17785703 (Pubitemid 350063804)
53. PG Richardson C Mitsiades T Hideshima KC Anderson 2006 Bortezomib: proteasome inhibition as an effective anticancer therapy Annu Rev Med 57 33 47 10.1146/annurev.med.57.042905.122625 1:CAS:528:DC%2BD28Xis1CksrY%3D 16409135 (Pubitemid 43261977)
54. RZ Orlowski TE Stinchcombe BS Mitchell, et al. 2002 Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies J Clin Oncol 20 22 4420 4427 10.1200/JCO.2002.01.133 1:CAS:528: DC%2BD38XosFCjs70%3D 12431963 (Pubitemid 35334752)
55. PG Richardson B Barlogie J Berenson, et al. 2003 A phase 2 study of bortezomib in relapsed, refractory myeloma [see comment] N Engl J Med 348 26 2609 2617 10.1056/NEJMoa030288 1:CAS:528:DC%2BD3sXkvVSksLs%3D 12826635 (Pubitemid 36741588)
56. S Jagannath B Barlogie J Berenson, et al. 2004 A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma British J Haematol 127 2 165 172 10.1111/j.1365-2141.2004.05188.x 1:CAS:528:DC%2BD2cXpvFait7g%3D (Pubitemid 39371809)
57. S Jagannath B Barlogie JR Berenson, et al. 2008 Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma Br J Haematol 143 4 537 540 18783399
58. PG Richardson P Sonneveld MW Schuster, et al. 2005 Bortezomib or high-dose dexamethasone for relapsed multiple myeloma [see comment] N Engl J Med 352 24 2487 2498 10.1056/NEJMoa043445 1:CAS:528:DC%2BD2MXltlaksLc%3D 15958804 (Pubitemid 41007864)
59. PG Richardson P Sonneveld M Schuster, et al. 2007 Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial Blood 110 10 3557 3560 10.1182/blood-2006-08-036947 1:CAS:528:DC%2BD2sXhtlarur3K 17690257 (Pubitemid 350159621)
60. T Hideshima P Richardson D Chauhan, et al. 2001 The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells Cancer Res 61 7 3071 3076 1:CAS:528: DC%2BD3MXivFGqsL0%3D 11306489
61. R Popat H Oakervee C Williams, et al. 2009 Bortezomib, low-dose intravenous melphalan, and dexamethasone for patients with relapsed multiple myeloma Br J Haematol 144 6 887 894 10.1111/j.1365-2141.2008.07572.x 1:CAS:528:DC%2BD1MXkt12ntb8%3D 19183191
62. J Berenson H Yang R Vescio, et al. 2008 Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-up Ann Hematol 87 8 623 631 10.1007/s00277-008-0501-0 1:CAS:528:DC%2BD1cXnvVOnurs%3D 18463870
63. E Terpos S Delimpasi K Anargyrou, et al. 2007 The combination of bortezomib, doxorubicin, and dexamethasone (PAD) is an effective regimen for high risk, newly diagnosed, patients with multiple myeloma, reduces bone resorption and normalizes angiopoietin-1 to angiopoietin-2 ratio ASH Ann Meet Abstr 110 11 3596
64. M Pineda-Roman M Zangari F van Rhee, et al. 2008 VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma Leukemia 22 7 1419 1427 10.1038/leu.2008.99 1:CAS:528:DC%2BD1cXosFSms78%3D 18432260 (Pubitemid 352006086)
65. A Palumbo F Gay S Bringhen, et al. 2008 Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma Ann Oncol 19 6 1160 1165 10.1093/annonc/mdn018 1:STN:280:DC%2BD1czktlWntg%3D%3D 18326520 (Pubitemid 351796343)
66. F Di Raimondo A Romano A Gorgone, et al. 2008 Salvage therapy with intravenous liposomal adryamicin (A), bortezomib (B), cyclophosphamide (C), and dexamethasone (D) (ABCD) in previously treated myeloma patients ASH Ann Meet Abstr 112 11 2779
67. A Chanan-Khan P Sonneveld MW Schuster, et al. 2008 Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study J Clin Oncol 26 29 4784 4790 10.1200/JCO.2007.14.9641 1:CAS:528:DC%2BD1cXhtlSqsb7K 18711175
68. JF San Miguel R Schlag NK Khuageva, et al. 2008 Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma N Engl J Med 359 9 906 917 10.1056/NEJMoa0801479 1:CAS:528:DC%2BD1cXhtVGms77K 18753647
69. P Richardson S Jagannath A Jakubowiak, et al. 2008 Lenalidomide, bortezomib, and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (MM): encouraging response rates and tolerability with correlation of outcome and adverse cytogenetics in a phase II study ASH Ann Meet Abstr 112 11 1742
70. MH Ma HH Yang K Parker, et al. 2003 The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents Clin Cancer Res 9 3 1136 1144 1:CAS:528: DC%2BD3sXhvFKitbo%3D 12631619
71. RZ Orlowski PM Voorhees RA Garcia, et al. 2005 Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies Blood 105 8 3058 3065 10.1182/blood-2004-07-2911 1:CAS:528:DC%2BD2MXjtlSmtbo%3D 15626743
72. RZ Orlowski A Nagler P Sonneveld, et al. 2007 Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression J Clin Oncol 25 25 3892 3901 10.1200/JCO.2006.10.5460 1:CAS:528:DC%2BD2sXhtFanu73M 17679727 (Pubitemid 47477266)
73. A Chanan-Khan KC Miller L Musial, et al. 2009 Bortezomib in combination with pegylated liposomal doxorubicin and thalidomide is an effective steroid independent salvage regimen for patients with relapsed or refractory multiple myeloma: results of a phase II clinical trial Leukemia Lymphoma 50 7 1096 1101 10.1080/10428190902912460 1:CAS:528:DC%2BD1MXnvVOnsLk%3D 19479618
74. R Baz E Walker MA Karam, et al. 2006 Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy Ann Oncol 17 12 1766 1771 10.1093/annonc/mdl313 1:STN:280:DC%2BD28jhtlWhtw%3D%3D 16980599 (Pubitemid 44884050)
75. S Ciolli F Leoni C Casini C Breschi V Santini A Bosi 2008 The addition of liposomal doxorubicin to bortezomib, thalidomide and dexamethasone significantly improves clinical outcome of advanced multiple myeloma British J Haematol 141 6 814 819 10.1111/j.1365-2141.2008.07147.x 1:CAS:528: DC%2BD1cXotlCqsr8%3D (Pubitemid 351724874)
76. M Offidani S Bringhen L Corvatta, et al. 2007 Thalidomide-dexamethasone plus pegylated liposomal doxorubicin vs. thalidomide-dexamethasone: a case-matched study in advanced multiple myeloma Eur J Haematol 78 4 297 302 10.1111/j.1600-0609.2007.00823.x 1:CAS:528:DC%2BD2sXkvFehu7g%3D 17286608 (Pubitemid 46365087)
77. LM Knudsen E Hippe M Hjorth E Holmberg J Westin 1994 Renal function in newly diagnosed multiple myeloma-a demographic study of 1353 patients. The Nordic Myeloma Study Group Eur J Haematol 53 4 207 212 1:STN:280: DyaK2M%2Fks1ajsg%3D%3D 7957804
78. S Jagannath B Barlogie J Berenson, et al. 2005 Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impaired renal function Cancer 103 6 1195 1200 10.1002/cncr.20888 1:CAS:528:DC%2BD2MXivFWgsL0%3D 15690325 (Pubitemid 40328090)
79. JF San-Miguel PG Richardson P Sonneveld, et al. 2008 Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study Leukemia 22 4 842 849 10.1038/sj.leu.2405087 1:CAS:528: DC%2BD1cXks12rtLw%3D 18200040 (Pubitemid 351552634)
80. P Tosi E Zamagni C Cellini, et al. 2004 Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure Eur J Haematol 73 2 98 103 10.1111/j.1600-0609.2004.00272.x 1:CAS:528:DC%2BD2cXmvVaisr4%3D 15245508 (Pubitemid 38980109)
81. E Harris J Behrens D Samson A Rahemtulla NH Russell JL Byrne 2003 Use of thalidomide in patients with myeloma and renal failure may be associated with unexplained hyperkalaemia British J Haematol 122 1 160 161 10.1046/j.1365-2141. 2003.04395-2.x 1:STN:280:DC%2BD3s3ps1Sjuw%3D%3D (Pubitemid 36819352)
82. Celegene. Celegene Package Insert.
83. PG Richardson H Briemberg S Jagannath, et al. 2006 Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib J Clin Oncol 24 19 3113 3120 10.1200/JCO.2005.04.7779 1:CAS:528:DC%2BD28XnslKhs7c%3D 16754936 (Pubitemid 46638949)
84. A Palumbo S Bringhen D Rossi, et al. 2009 A phase III study of VMPT versus VMP in newly diagnosed elderly myeloma patients J Clin Oncol 27 15 s 437
85. S Lonial PG Richardson J San Miguel, et al. 2008 Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma British J Haematol 143 2 222 229 10.1111/j.1365-2141.2008.07321.x 1:CAS:528:DC%2BD1cXhtlWisb%2FP
86. Barlogie B, Attal M, Crowley J, Harousseau J. Long-term follow-up of autotransplant (AT)-supported high-dose melphalan (hdm) for multiple myeloma (MM): update of Intergroup Francophone du Myelome (IFM), Southwest Oncology Group (SWOG), and Arkansas (ARK) total therapy (TT) trials. J Clin Oncol 2009;27(15 s):438.
87. DJ Kuhn Q Chen PM Voorhees, et al. 2007 Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma Blood 110 9 3281 3290 10.1182/blood-2007-01-065888 1:CAS:528:DC%2BD2sXht1yqur3L 17591945 (Pubitemid 350106321)
88. R Vij M Wang R Orlowski, et al. 2008 Initial results of PX-171-004, an open-label, single-arm, phase II study of carfilzomib (CFZ) in patients with relapsed myeloma (MM) ASH Ann Meet Abstr 112 11 865
89. Vij R, Wang M, Orlowski R, et al. PX-171-004, a multicenter phase II study of carfilzomib (CFZ) in patients with relapsed myeloma: an efficacy update. J Clin Oncol. 2009;27:443.
90. CS Mitsiades NS Mitsiades CJ McMullan, et al. 2004 Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications Proc Natl Acad Sci USA 101 2 540 545 10.1073/pnas. 2536759100 1:CAS:528:DC%2BD2cXmsFGnsA%3D%3D 14695887 (Pubitemid 38084672)
91. P Richardson C Mitsiades K Colson, et al. 2008 Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma Leukemia Lymphoma 49 3 502 507 10.1080/10428190701817258 1:CAS:528:DC%2BD1cXit1Cmsbc%3D 18297527 (Pubitemid 351298334)
92. D Weber AZ Badros S Jagannath, et al. 2008 Vorinostat plus bortezomib for the treatment of relapsed/refractory multiple myeloma: early clinical experience ASH Ann Meet Abstr 112 11 871
93. T Hideshima L Catley H Yasui, et al. 2006 Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells Blood 107 10 4053 4062 10.1182/blood-2005-08-3434 1:CAS:528:DC%2BD28XkvFWgsrs%3D 16418332 (Pubitemid 43726814)
94. A Jakubowiak P Richardson TM Zimmerman, et al. 2008 Phase I results of perifosine (KRX-0401) in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (MM) ASH Ann Meet Abstr 112 11 3691
95. P Richardson J Wolf A Jakubowiak, et al. 2008 Phase I/II results of a multicenter trial of perifosine (KRX-0401) + bortezomib in patients with relapsed or relapsed/refractory multiple myeloma who were previously relapsed from or refractory to bortezomib ASH Ann Meet Abstr 112 11 870
96. PM Voorhees Q Chen GW Small, et al. 2009 Targeted inhibition of interleukin-6 with CNTO 328 sensitizes pre-clinical models of multiple myeloma to dexamethasone-mediated cell death Br J Haematol 145 4 481 490 10.1111/j.1365-2141.2009.07647.x 1:CAS:528:DC%2BD1MXmsVertrg%3D 19344406
97. Voorhees PM, Manges R, Somlo G, Lentzsch S, Jagannath S, Sonneveld P, Frank R, Zweegman S, Wijermans P, Thomas S. A phase II multicenter study of CNTO 328, an anti-IL-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma. J Clin Oncol. 2009;27(15 s):440.
98. J-F Rossi RF Manges HJ Sutherland, et al. 2008 Preliminary results of CNTO 328, an anti-interleukin-6 monoclonal antibody, in combination with bortezomib in the treatment of relapsed or refractory multiple myeloma ASH Ann Meet Abstr 112 11 867
99. EL Davenport HE Moore AS Dunlop, et al. 2007 Heat shock protein inhibition is associated with activation of the unfolded protein response pathway in myeloma plasma cells Blood 110 7 2641 2649 10.1182/blood-2006-11- 053728 1:CAS:528:DC%2BD2sXhtFCnsbnM 17525289 (Pubitemid 47523188)
100. CS Mitsiades NS Mitsiades CJ McMullan, et al. 2006 Antimyeloma activity of heat shock protein-90 inhibition Blood 107 3 1092 1100 10.1182/blood-2005-03- 1158 1:CAS:528:DC%2BD28Xht1Ont7k%3D 16234364 (Pubitemid 43156310)
101. Richardson P, Chanan-Khan A, Lonial S, Krishnan A, Carroll M, Alsina M, Albitar M, Berman D, Kaplita S, Anderson K. Tanespimycin plus bortezomib in patients with relapsed and refractory multiple myeloma: final results of a phase I/II study. J Clin Oncol. 2009;27(15 s):434.
102. E Terpos E Kastritis M Roussou, et al. 2008 The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed//refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis Leukemia 22 12 2247 2256 10.1038/leu.2008.235 1:CAS:528:DC%2BD1cXhsFWjtb7K 18769451
103. M Offidani L Corvatta M Marconi, et al. 2006 Low-dose thalidomide with pegylated liposomal doxorubicin and high-dose dexamethasone for relapsed/refractory multiple myeloma: a prospective, multicenter, phase II study Haematologica 91 1 133 136 1:CAS:528:DC%2BD28XitFWgsbY%3D 16434383
104. S Jagannath R Vij AK Stewart, et al. 2008 Initial results of PX-171-003, an open-label, single-arm, phase II study of carfilzomib (CFZ) in patients with relapsed and refractory multiple myeloma (MM) ASH Ann Meet Abstr 112 11 864
105. Niesvizky R, Bensinger W, Vallone A, Gutierrez L, Kunkel. PX-171-006: Phase 1b multicenter dose escalation study of carfilzomib plus lenalidomide and low dose dexamethasone in relapsed and refractory multiple myeloma: preliminary results. J Clin Oncol. 2009;27(15 s):444.
106. D Siegel D Weber CS Mitsiades, et al. 2008 A phase I study of vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma ASH Ann Meet Abstr 112 11 3705
107. MQ Lacy SR Hayman MA Gertz, et al. 2008 Pomalidomide (CC4047) plus low-dose dexamethasone (Pom/dex) is highly effective therapy in relapsed multiple myeloma ASH Ann Meet Abstr 112 11 866
108. Dd Siegel O Sezer JF San Miguel, et al. 2008 A phase IB, multicenter, open-label, dose-escalation study of Oral panobinostat (LBH589) and I. V. bortezomib in patients with relapsed multiple myeloma ASH Ann Meet Abstr 112 11 2781
109. A Badros S Philip R Niesvizky, et al. 2007 Phase I trial of suberoylanilide hydroxamic acid (SAHA) + bortezomib (Bort) in relapsed multiple myeloma (MM) patients (pts) ASH Ann Meet Abstr 110 11 1168
110. Hofmeister C, Richardson P, Zimmerman T, Spear M, Palladino M, Longenecker A, Cropp G, Lloyd G, Hannah A, Anderson K. Clinical trial of the novel structure proteasome inhibitor NPI-0052 in patients with relapsed and relapsed/refractory multiple myeloma. J Clin Oncol. 2009;27(15 s):435.
111. SJ Harrison H Quach K Yuen, et al. 2008 High response rates with the combination of bortezomib, dexamethasone and the pan-histone deacetylase inhibitor romidepsin in patients with relapsed or refractory multiple myeloma in a phase I/II clinical trial ASH Ann Meet Abstr 112 11 3698
112. IM Ghobrial N Munshi R Schlossman, et al. 2008 Phase I trial of CCI-779 (Temsirolimus) and weekly bortezomib in relapsed and/or refractory multiple myeloma ASH Ann Meet Abstr 112 11 3696